Citigroup initiated coverage on Krystal Biotech with a new price target

10/12/23 8:56:45 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Citigroup initiated coverage of Krystal Biotech with a rating of Buy and set a new price target of $160.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$KRYS

Date	Price Target	Rating	Analyst
3/5/2025	$245.00	Buy	Jefferies
8/6/2024	$195.00 → $204.00	Buy → Neutral	Citigroup
11/20/2023	$160.00	Buy	Goldman
10/24/2023	$100.00	Overweight	Cantor Fitzgerald
10/12/2023	$160.00	Buy	Citigroup
9/7/2023	$154.00	Buy	Berenberg
4/18/2023	$102.00	Buy	Stifel
2/28/2023	$79.00 → $124.00	Neutral → Buy	Goldman